


Apoptosis inducer 4

Cat. No.:	HY-146092
CAS No.:	2408050-83-7
Molecular Formula:	C ₄₁ H ₅₀ O ₁₁ S ₃
Molecular Weight:	815.02
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Apoptosis inducer 4 (Compound 12b) is an apoptosis inducer with anticancer activities ^[1] .																		
In Vitro	<p>Apoptosis inducer 4 (Compound 12b) (0-50 μM, 72 h) shows antiproliferative activities against cancer cells without obvious cytotoxicity against normal cells^[1].</p> <p>Apoptosis inducer 4 (0-2 μM, 48 h) causes cell cycle arrest at S phase in K562 cells and G1 phase in HepG2 cells^[1].</p> <p>Apoptosis inducer 4 (0-4 μM, 24 and 48 h) induces pyknosis in K562 cells, and induces mitochondrial membrane potentials decline^[1].</p> <p>Apoptosis inducer 4 (0-2 μM, 72 h) induces apoptosis in K562 and HepG2 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC</td> </tr> <tr> <td>Concentration:</td> <td>0-50 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Showed antiproliferative activities with IC₅₀ values of 2.57 \pm 0.12, 16.15 \pm 1.02, 5.81 \pm 1.17, 12.94 \pm 0.88, 0.95 \pm 0.06, 17.59 \pm 0.93 and >50 μM against HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC cells, respectively.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 and HepG2 cells</td> </tr> <tr> <td>Concentration:</td> <td>K562 and HepG2 cells</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Arrested K562 cell cycle at S phase and HepG2 cell at G1 phase.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 and HepG2 cells</td> </tr> </table>	Cell Line:	HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC	Concentration:	0-50 μ M	Incubation Time:	72 h	Result:	Showed antiproliferative activities with IC ₅₀ values of 2.57 \pm 0.12, 16.15 \pm 1.02, 5.81 \pm 1.17, 12.94 \pm 0.88, 0.95 \pm 0.06, 17.59 \pm 0.93 and >50 μ M against HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC cells, respectively.	Cell Line:	K562 and HepG2 cells	Concentration:	K562 and HepG2 cells	Incubation Time:	48 h	Result:	Arrested K562 cell cycle at S phase and HepG2 cell at G1 phase.	Cell Line:	K562 and HepG2 cells
Cell Line:	HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC																		
Concentration:	0-50 μ M																		
Incubation Time:	72 h																		
Result:	Showed antiproliferative activities with IC ₅₀ values of 2.57 \pm 0.12, 16.15 \pm 1.02, 5.81 \pm 1.17, 12.94 \pm 0.88, 0.95 \pm 0.06, 17.59 \pm 0.93 and >50 μ M against HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC cells, respectively.																		
Cell Line:	K562 and HepG2 cells																		
Concentration:	K562 and HepG2 cells																		
Incubation Time:	48 h																		
Result:	Arrested K562 cell cycle at S phase and HepG2 cell at G1 phase.																		
Cell Line:	K562 and HepG2 cells																		

Concentration:	K562 and HepG2 cells
Incubation Time:	72 h
Result:	Apoptotic ratios of K562 and HepG2 cells obviously increased in a concentration-dependent manner.

REFERENCES

[1]. Li H, et al. Hydrogen sulfide releasing oridonin derivatives induce apoptosis through extrinsic and intrinsic pathways. Eur J Med Chem. 2020 Feb 1;187:111978.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA